**Question:** Antibody found in patients of myasthenia gravis is directed against -

**Core Concept:** Myasthenia gravis (MG) is a neuromuscular autoimmune disorder where the immune system attacks the acetylcholine receptors (AChRs) on the neuromuscular junction (NMJ), leading to muscle weakness and fatigue.

**Why the Correct Answer is Right:** The correct answer is **Option D**: acetylcholine receptor antibodies (AChR-Abs).

In myasthenia gravis, autoantibodies produced by the patient's immune system bind to the nicotinic acetylcholine receptors (nAChRs) on the postsynaptic membrane of the neuromuscular junction (NMJ). This binding blocks the acetylcholine from binding to its receptor, reducing the effectiveness of the neuromuscular transmission. This results in muscle weakness and fatigue, the defining symptoms of myasthenia gravis.

**Why Each Wrong Option is Incorrect:**

**Option A (Muscle-specific kinase [MuSK]-Abs):** MuSK-Abs are also autoantibodies found in myasthenia gravis patients. However, they bind to the muscle-specific kinase (MuSK) rather than the acetylcholine receptors (AChRs), leading to a different pathophysiology than AChR-Abs.

**Option B (Receptor tyrosine kinase [Lrp4]-Abs):** Lrp4-Abs are also found in myasthenia gravis patients. They bind to the low-density lipoprotein receptor-related protein 4 (Lrp4), another component of the postsynaptic membrane involved in NMJ function. However, unlike AChR-Abs and MuSK-Abs, Lrp4-Abs have a different pathophysiology and may co-exist with AChR-Abs or MuSK-Abs.

**Option C (Anti-acetylcholine esterase [AChE]-Abs):** AChE-Abs are not found in myasthenia gravis patients. Acetylcholinesterase (AChE) is an enzyme that breaks down acetylcholine at the NMJ, preventing excessive acetylcholine release. In myasthenia gravis, autoantibodies target AChRs or MuSK, leading to a different pathogenesis than AChE inhibition.

**Why the Correct Answer is Right:**

The correct answer, **Option D (Anti-acetylcholine receptor [AChR]-Abs)**, is chosen because these autoantibodies directly target the acetylcholine receptors (AChRs) at the neuromuscular junction (NMJ). The binding of AChR-Abs impairs the normal functioning of AChRs, leading to reduced acetylcholine release and decreased neuromuscular transmission, resulting in the characteristic symptoms of myasthenia gravis.

**Clinical Pearls:**

1. Myasthenia gravis is an autoimmune disorder where the immune system mistakenly attacks the NMJ, affecting neuromuscular transmission.
2. AChR-Abs are found in approximately